Eriksson, Marika I
Hietala, Kustaa
Summanen, Paula
Harjutsalo, Valma
Putaala, Jukka
Ylinen, Anni
Hägg-Holmberg, Stefanie
Groop, Per-Henrik
Thorn, Lena M
,
Funding for this research was provided by:
University of Helsinki
Article History
Received: 7 February 2024
Accepted: 12 April 2024
First Online: 25 April 2024
Declarations
:
: The study was performed in accordance with the Declaration of Helsinki. The Ethics Committee of Helsinki University Hospital approved the study protocol, and each participant has provided their written informed consent.
: Not applicable.
: M.I.E. is a shareholder of BCB Medical Oy. P.S. is a shareholder of Orion Oy and Revenio Group Oyj. P-H G has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestle, Novartis, Novo Nordisk and Sanofi; and has received lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Novartis, Novo Nordisk, PeerVoice and Sanofi. The other authors declare no disclosure.